JP3368531B2 - Indirect agglutination immunoassay - Google Patents

Indirect agglutination immunoassay

Info

Publication number
JP3368531B2
JP3368531B2 JP34193397A JP34193397A JP3368531B2 JP 3368531 B2 JP3368531 B2 JP 3368531B2 JP 34193397 A JP34193397 A JP 34193397A JP 34193397 A JP34193397 A JP 34193397A JP 3368531 B2 JP3368531 B2 JP 3368531B2
Authority
JP
Japan
Prior art keywords
well
sample
reaction
agglutination
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP34193397A
Other languages
Japanese (ja)
Other versions
JPH11160315A (en
Inventor
智雄 斉藤
和典 相馬
勉 斉藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Priority to JP34193397A priority Critical patent/JP3368531B2/en
Publication of JPH11160315A publication Critical patent/JPH11160315A/en
Application granted granted Critical
Publication of JP3368531B2 publication Critical patent/JP3368531B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Automatic Analysis And Handling Materials Therefor (AREA)

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、1つの検体につい
て、3つの異なる条件で凝集反応を行い、得られた凝集
結果から非特異反応によらず検体の陽性・陰性を判定す
ることができる間接凝集免疫測定方法に関する。詳しく
は、一つの検体について、検体溶液を含む第1ウェル
と、反応抑制物質を含有する検体溶液を含む第2ウェル
と、第1ウェルよりも希釈倍率の高い検体溶液を含む第
3ウェルとを用意し、これらの3つのウェルにおいて測
定試薬との免疫反応を行い、得られた凝集結果から非特
異反応によらず検体の陽性・陰性を判定することができ
る間接凝集免疫測定方法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is an indirect method capable of performing an agglutination reaction on one sample under three different conditions, and determining the positive or negative of the sample from the obtained agglutination result regardless of the non-specific reaction. An agglutination immunoassay method. Specifically, for one specimen, a first well containing a specimen solution, a second well containing a specimen solution containing a reaction-inhibiting substance, and a third well containing a specimen solution having a higher dilution ratio than the first well are provided. The present invention relates to an indirect agglutination immunoassay method in which an immunoreaction with a measurement reagent is prepared in these three wells, and positive / negative of a sample can be determined from the obtained agglutination result without depending on a nonspecific reaction.

【0002】[0002]

【従来の技術】従来、検体中の抗原、抗体等の免疫測定
物質を測定するために間接凝集免疫測定方法が用いられ
ている。間接凝集免疫測定方法は、反応後に得られた凝
集像から抗原抗体反応による免疫測定物質を測定する方
法であるが、時として陰性の検体であっても非特異反応
による凝集を起こす可能性があることを考慮に入れなけ
ればならない。
2. Description of the Related Art Conventionally, an indirect agglutination immunoassay method has been used to measure immunoassay substances such as antigens and antibodies in a sample. The indirect agglutination immunoassay method is a method of measuring an immunoassay substance by an antigen-antibody reaction from an agglutination image obtained after the reaction, but sometimes even a negative specimen may cause agglutination by a nonspecific reaction. That must be taken into consideration.

【0003】従来の測定方法としては1つのウェルを用
いる方法と2つのウェルを用いる方法とがある。1つの
ウェルを用いる方法は、検体溶液として非特異反応によ
る凝集が起こらない希釈倍率のものを用いる測定方法で
ある。
Conventional measuring methods include a method using one well and a method using two wells. The method using one well is a measurement method using a sample solution having a dilution ratio that does not cause aggregation due to a non-specific reaction.

【0004】2つのウェルを用いる方法は、一方のウェ
ルには感作粒子を含む溶液を滴下し、もう一方のウェル
には未感作粒子を含む溶液を滴下する測定方法である。
ここで、この2つのウェルは希釈倍率を低くしているた
め非特異反応による凝集が起こる可能性があるものであ
る。1つのウェルを用いた測定方法及び2つのウェルを
用いた測定方法共に、反応を十分に行った後それぞれの
ウェルの凝集結果から測定検体の陽性・陰性を判定する
ものである。このような測定方法を行い陽性・陰性を判
断していた。
The method using two wells is a measuring method in which a solution containing sensitized particles is dropped in one well and a solution containing unsensitized particles is dropped in the other well.
Here, since the dilution ratio of these two wells is low, aggregation due to non-specific reaction may occur. In both the measuring method using one well and the measuring method using two wells, the positive / negative of the measurement sample is judged from the agglutination result of each well after sufficient reaction. Positive / negative was judged by performing such a measuring method.

【0005】[0005]

【発明が解決しようとする課題】従来技術において、1
つのウェルでの測定方法では、陽性・陰性の測定及び判
定を容易にすることができるが、非特異反応が起こらな
い濃度(通常、原検体の20倍以上の希釈倍率)にまで
検体を希釈しているため、感度が低かった。また、2つ
のウェルでの測定方法では、1つのウェルでの測定より
も高い濃度の検体を用いているため感度は高いが、この
測定方法では、濃度が高いため非特異反応が起こる可能
性があり、非特異反応による凝集が起こっている場合に
は、抗原感作粒子を滴下したウェルの凝集が、非特異反
応に起因するものであるのか陽性検体に起因するもので
あるのか判断することができず、この段階で陽性・陰性
を判定することはできない、という欠点を有していた。
SUMMARY OF THE INVENTION In the prior art, 1
The two-well assay method can facilitate positive and negative measurements and determinations, but dilute the sample to a concentration that does not cause nonspecific reaction (usually a dilution factor of 20 times or more that of the original sample). Therefore, the sensitivity was low. In addition, the two-well measurement method has high sensitivity because it uses a higher concentration of sample than the one-well measurement, but this measurement method has a high concentration, which may cause nonspecific reaction. If there is aggregation due to a non-specific reaction, it is possible to determine whether the aggregation in the well in which the antigen-sensitized particles have been dropped is due to a non-specific reaction or a positive sample. It was not possible, and there was a drawback that it was not possible to judge positive / negative at this stage.

【0006】このように、定性試験において1つのウェ
ルを用いる測定方法の場合はさらなる感度の向上が求め
られており、また、2つのウェルを用いる測定方法の場
合には、定性試験において陽性・陰性の判定を完全にす
ることができないため、本来陰性検体であるが非特異反
応のために判定不能となる検体についても、特異反応抑
制物質を用いて吸収操作を行い定量試験を行わなければ
ならなかった。この場合には非特異反応による凝集を起
こす陰性検体についても定量試験を行わなければ最終的
な判定を下すことができず、多量の検体を処理する場合
には、このような不必要な測定検体の増加に伴い測定時
間が増加することが問題となっていた。
As described above, further improvement in sensitivity is required in the case of the assay method using one well in the qualitative test, and in the case of the assay method using two wells, positive / negative in the qualitative test. Since it is not possible to make a complete determination, it is necessary to perform a quantitative test by performing an absorption operation using a specific reaction-suppressing substance even for a sample that is originally a negative sample but cannot be determined due to a nonspecific reaction. It was In this case, a final determination cannot be made without conducting a quantitative test for negative samples that cause aggregation due to non-specific reactions. It has been a problem that the measurement time increases with the increase of.

【0007】[0007]

【課題を解決するための手段】本発明者らは、従来の課
題を解決するため鋭意検討した結果、新規な間接凝集免
疫測定方法を見出し本発明を完成するに至った。本発明
は、一回の測定で検体の陽性・陰性を判定することがで
きる間接凝集免疫測定方法である。
Means for Solving the Problems As a result of intensive studies to solve the conventional problems, the present inventors have found a novel indirect agglutination immunoassay method and completed the present invention. The present invention is an indirect agglutination immunoassay method capable of determining positive / negative of a sample by a single measurement.

【0008】本発明の測定を行うには、まず、1つの検
体について、検体溶液を含む第1ウェルと、反応抑制物
質を含有する検体溶液を含む第2ウェルと、第1ウェル
よりも希釈倍率の高い検体溶液を含む第3ウェルとを用
意する。この第1及び第3ウェルには反応抑制物質は添
加されていない。
To carry out the measurement of the present invention, first, for one sample, a first well containing a sample solution, a second well containing a sample solution containing a reaction-inhibiting substance, and a dilution ratio higher than the first well And a third well containing a high analyte solution. The reaction suppressing substance is not added to the first and third wells.

【0009】このように作成された溶液に測定物質と特
異的に反応する抗原又は抗体を感作した粒子を加え、攪
拌する。この反応後の各ウェルの凝集結果の組み合わせ
により、検体の判定を効率的に行うことができる。それ
ぞれのウェルに関して陽性と判定した場合は+、陰性と
判定した場合は−と表記すると、得られた凝集結果によ
り検体を次のように分類することができる。
Particles sensitized with an antigen or an antibody that specifically reacts with the substance to be measured are added to the solution thus prepared and stirred. The combination of the agglutination results of each well after this reaction enables efficient determination of the sample. If each well is determined to be positive, it is expressed as +, and if it is determined to be negative, it is expressed as −, and the samples can be classified as follows based on the obtained aggregation result.

【0010】まず、陽性検体については、次の3つに分
類することができる。 力価が第3ウェル以上(高力価)である陽性検体の場
合は、第1ウェルは+、第2ウェルは高力価のために抑
制が完全にかからず+、第3ウェルも高力価のために希
釈倍率以上の力価であるので+となる。このとき、非特
異反応による凝集が起こっていても全て+となるため、
最終判定は変わらない。 力価が第3ウェル以下(低力価)であり、非特異反応
による凝集が起こっていない陽性検体の場合は、第1ウ
ェルは+、第2ウェルは抑制が完全にかかり−、第3ウ
ェルも低力価であるために希釈により−となる。 力価が第3ウェル以下であり、非特異反応による凝集
も起こっている陽性検体の場合には第1ウェルは+、第
2ウェルは完全に抑制がかかるが非特異反応による凝集
のため+であり、第3ウェルは両反応とも希釈により抑
えられ−となる。
First, positive samples can be classified into the following three types. In the case of a positive sample with a titer of 3 wells or more (high titer), the 1st well is +, the 2nd well is not completely suppressed due to the high titer, and the 3rd well is also high. Since the titer is a titer equal to or higher than the dilution ratio, it becomes +. At this time, even if aggregation due to non-specific reaction occurs, all become +,
The final decision remains the same. When the titer is 3 wells or less (low titer) and the agglutination due to non-specific reaction does not occur, the first well is +, the second well is completely suppressed-, the third well. Since it has a low titer, it becomes − upon dilution. In the case of a positive sample with a titer of 3 wells or less and agglutination due to non-specific reaction, the first well is +, and the second well is completely suppressed, but + due to agglutination due to non-specific reaction. Yes, the third well is suppressed by dilution in both reactions.

【0011】次に、陰性検体については、次の2つに分
類することができる。 非特異反応による凝集が起こっていない陰性検体の場
合は、目的の反応及び非特異反応共に起こっていないの
で、全てのウェルで−となる。 非特異反応による凝集が起こっている陰性検体の場合
には、第1ウェルは非特異反応により凝集が起こり+、
第2ウェルの反応抑制物質は目的とする反応は阻害する
が非特異反応は阻害しないのでやはり+となり、第3ウ
ェルでは希釈による非特異反応による凝集は起こらない
ので−となるものである。
Next, the negative samples can be classified into the following two types. In the case of a negative sample in which agglutination due to a non-specific reaction has not occurred, neither the target reaction nor the non-specific reaction has occurred, so that the value is − in all wells. In the case of a negative sample in which agglutination has occurred due to a non-specific reaction, agglutination has occurred in the first well due to a non-specific reaction +,
The reaction-suppressing substance in the second well inhibits the desired reaction but does not inhibit the non-specific reaction, so that it also becomes +, and in the third well, the agglutination due to the non-specific reaction does not occur, so that it becomes −.

【0012】以上の結果において、ととは一見同じ
結果のように思えるが、実際には第1ウェルと第2ウェ
ルとの凝集像の差により、どちらであるか判断すること
が可能である。最終判定は、第1及び第2ウェルの凝集
像に差がみられない場合はと判定し、第1及び第2ウ
ェルを比較したときに、第1ウェルが強陽性像、第2ウ
ェルが弱陽性像であった場合にはと判定を行うもので
ある。最終判定は上記のように凝集結果の組み合わせか
ら行うものであり、まとめたものを表1に示す。このと
き、の第1ウェルと第2ウェルは2のn乗希釈を用い
る凝集法における1管以上の差が認められるものであ
る。
In the above results, and seem to be the same as each other at first glance, but it is possible to judge which is actually based on the difference in agglutination image between the first well and the second well. The final judgment was made when there was no difference in the agglutination images of the first and second wells, and when the first and second wells were compared, the first well had a strong positive image and the second well had a weak image. When the image is positive, it is determined. The final judgment is made from the combination of the aggregation results as described above, and Table 1 shows a summary. At this time, the difference between the first well and the second well of one tube or more in the agglutination method using 2 n-th power dilution is recognized.

【0013】[0013]

【表1】 ※ は第1ウェルと第2ウェルとの凝集像に差がほとんどみられない場合であ り、は第1ウェルと第2ウェルの凝集像に1管以上の差がみられる場合であ る。[Table 1] * Indicates that there is almost no difference in the agglutination image between the first well and the second well, and indicates that there is a difference of 1 or more tubes in the agglutination image between the first well and the second well.

【0014】本発明において、第2ウェルの反応抑制物
質の含有量と第3ウェルの希釈倍率とが特異反応の凝集
を同程度起こるように調整し反応を行うことが好まし
く、反応抑制物質と希釈倍率との関係は使用する抗原、
抗体及び反応抑制物質により適宜調整されるものであ
る。
In the present invention, it is preferable that the reaction is controlled by adjusting the content of the reaction-inhibiting substance in the second well and the dilution ratio of the third well so that the agglutination of the specific reaction occurs to the same extent. The relationship with the magnification is the antigen used,
It is appropriately adjusted depending on the antibody and the reaction suppressing substance.

【0015】測定試薬に用いる粒子は、間接凝集免疫測
定で一般に用いられる粒子、例えばヒト、羊、ニワト
リ、ヤギ等の動物赤血球、ゼラチン、ラテックス、磁性
粒子等で被覆された人工固体粒子等の免疫学的に不活性
な粒子、を挙げることができる。
Particles used as the measuring reagent are particles generally used in indirect agglutination immunoassay, such as animal red blood cells such as human, sheep, chicken, goat and the like, artificial solid particles coated with gelatin, latex, magnetic particles and the like. Mention may be made of particles which are biologically inert.

【0016】間接凝集免疫測定方法としては、用いる粒
子によって、赤血球凝集免疫測定方法、ラテックス凝集
免疫測定方法、磁力によって沈降を促進させる凝集免疫
測定方法、特開平3−191864号に記載されている
磁力によって粒子を強制的に容器の底部に集めた後、粒
子を流れださせる凝集免疫測定方法等を挙げることがで
きる。
As the indirect agglutination immunoassay method, depending on the particles used, a red blood cell agglutination immunoassay method, a latex agglutination immunoassay method, an agglutination immunoassay method of promoting sedimentation by magnetic force, and the magnetic force described in JP-A-3-191864. An agglutination immunoassay method in which the particles are forcibly collected at the bottom of the container and then the particles are made to flow out can be mentioned.

【0017】また、本発明に用いる反応抑制物質は、抗
原測定系では抗体を使用することができる。この抗体は
ポリクローナル抗体、モノクローナル抗体のいずれでも
よく、感作粒子に結合した抗体と同一のものでもよいが
通常は異なるほうが好ましい。また、抗体を測定する系
では測定する抗体に対する抗原であればよい。これに用
いる抗原は天然抗原、遺伝子組み換え抗原、合成抗原の
いずれも用いることができ、抗原測定系と同様に感作抗
原と異なるほうが好ましい。
As the reaction-suppressing substance used in the present invention, an antibody can be used in the antigen measuring system. This antibody may be a polyclonal antibody or a monoclonal antibody, and may be the same as the antibody bound to the sensitized particles, but it is usually preferable to be different. Further, in an antibody measuring system, any antigen may be used as long as it is an antigen against the antibody to be measured. As the antigen used for this purpose, any of natural antigen, recombinant antigen and synthetic antigen can be used, and it is preferable to be different from the sensitizing antigen as in the antigen measurement system.

【0018】本明細書において、濃度とは実際に反応を
行う際の測定試薬も含んだ濃度、すなわち終濃度をい
う。倍数による表現では、原検体を基準とした倍率を希
釈倍率として表現しているものである。第3ウェルの非
特異反応が起こらない倍率に希釈された濃度は測定する
検体中の免疫測定物質や検体の種類によって適宜好まし
い希釈濃度を選択することができる。通常は、希釈倍率
が原検体の20倍以上であることが好ましく、32倍以
上であることが特に好ましい。
In the present specification, the term "concentration" refers to a concentration that also includes a measurement reagent for actually performing the reaction, that is, a final concentration. In the expression using a multiple, the magnification based on the original sample is expressed as the dilution ratio. The concentration of the third well diluted to such a degree that non-specific reaction does not occur can be appropriately selected depending on the type of immunoassay substance or sample in the sample to be measured. Usually, the dilution ratio is preferably 20 times or more, and particularly preferably 32 times or more that of the original sample.

【0019】[0019]

【実施例】本発明を、以下参考例及び実施例により更に
詳細に説明する。
The present invention will be described in more detail with reference to Reference Examples and Examples below.

【0020】(参考例1) 間接凝集免疫反応用感作粒子の調整 特公平3−17103号に記載された方法に従って、ゼ
ラチン、アラビアゴム、ヘキサメタリン酸ナトリウム及
びフェリコロイドの混合物を不溶化することにより平均
粒径2.0μmのゼラチン磁性粒子を得た。このゼラチ
ン粒子をポリキノンで処理しポリクローナル抗HBs抗
体を感作し、抗HBs抗体感作磁性粒子を調整した。
Reference Example 1 Preparation of Sensitized Particles for Indirect Aggregation Immune Reaction In accordance with the method described in Japanese Patent Publication No. 3-17103, gelatin, gum arabic, sodium hexametaphosphate and ferric colloid were insolubilized to obtain an average. Gelatin magnetic particles having a particle size of 2.0 μm were obtained. The gelatin particles were treated with polyquinone to sensitize a polyclonal anti-HBs antibody to prepare anti-HBs antibody-sensitized magnetic particles.

【0021】(参考例2) 反応抑制物質含有希釈液の調整 希釈液(0.15M リン酸緩衝溶液 pH7.2、
0.1%NaN3 、0.25%アラビアゴム、1%NR
S、1%SH−NRS、1%Heat−Gelati
n、0.2mg/mLM38B2)にモノクローナル抗
HBs抗体(HB135)を937.5ng/mLの濃
度になるように添加し、それを本発明の抑制試験用の検
体希釈液とした。
Reference Example 2 Preparation of Diluting Solution Containing Reaction Inhibiting Substance Diluting Solution (0.15 M Phosphate Buffer Solution pH 7.2,
0.1% NaN 3 , 0.25% gum arabic, 1% NR
S, 1% SH-NRS, 1% Heat-Gerati
n, 0.2 mg / mL M38B2) to which a monoclonal anti-HBs antibody (HB135) was added so as to have a concentration of 937.5 ng / mL, which was used as a sample diluent for the inhibition test of the present invention.

【0022】(実施例1) HBs抗原の測定 V型マイクロプレートの第1及び第3ウェルに検体希釈
液をそれぞれ40μL、25μL、第2ウェルに抑制試
験用検体希釈液40μL、それに希釈用として使用する
ウェルに検体希釈液25μLを加えた。続いて、検体で
あるHBs抗原を含有する希釈検体、RIA陽性検体、
RIA陰性検体及びRIA陰性検体(間接凝集免疫測定
方法では判定不能)のそれぞれについて次のように各ウ
ェルの調製を行った。検体を第1及び第2ウェルに10
μLずつ加え、攪拌後、第1ウェルから25μLを取
り、希釈用ウェルに加え、攪拌、そして希釈用ウェルか
ら25μLを取り、第3ウェルに加え、攪拌し、第3ウ
ェルから25μLを取り廃棄した。第2ウェルは25μ
Lを取り、廃棄した。10分間静置後(吸収時間)、参
考例1で調整した抗HBs抗体感作磁性ゼラチン粒子の
0.2%含有分散液を25μLずつ、第1〜3ウェルに
加え。5分間攪拌し、磁石を用いた沈降促進台に90秒
間静置後、パターン判定台にてマイクロプレートを90
秒間、60度に傾け、マイクロプレートのウェル底部の
粒子の流れだしを行い凝集パターンを形成させ、免疫反
応の有無を判定した。第1〜3ウエルのそれぞれの凝集
パターンの組み合わせにより、測定検体が陽性であるの
か陰性であるのかを判定した。ここで、流れだしの長さ
が≦3.00mmを陽性(+)、>3.00mmを陰性
(−)と判定した。第1〜3ウェルの結果から最終判定
を行い、その結果を表2に示す。表2における長さは流
れだしの長さであり、単位はmmである。第1ウェル及
び第2ウェルが+、第3ウェルが−の検体については、
第1ウェルと第2ウェルの流れだしの長さの差によって
非特異反応による凝集を含むか否かを判断し、最終判定
を行った。ここでは、流れだしの長さの差が0.6mm
以上である場合に、第1ウェルは非特異反応による凝集
を含むと判断する。(0.6mmは凝集法における再現
性幅±1管に相当する。) 測定した検体(1)〜(8)の全てについて、表2のよ
うにRIAと同一の測定結果が得られた。
Example 1 Measurement of HBs Antigen 40 μL and 25 μL of a sample diluent in the first and third wells of a V-type microplate, 40 μL of a sample diluent for an inhibition test in the second well, and use for dilution 25 μL of the sample diluent was added to each well. Then, a diluted sample containing the HBs antigen, a RIA positive sample,
Each well was prepared as follows for each of the RIA-negative sample and the RIA-negative sample (which cannot be determined by the indirect agglutination immunoassay method). 10 samples in the first and second wells
μL was added to each well, and after stirring, 25 μL was taken from the first well, added to the well for dilution, stirred, and 25 μL was taken from the well for dilution, added to the third well, stirred, and 25 μL was taken from the third well and discarded. . The second well is 25μ
L was taken and discarded. After standing for 10 minutes (absorption time), 25 μL of a dispersion containing 0.2% of anti-HBs antibody-sensitized magnetic gelatin particles prepared in Reference Example 1 was added to the first to third wells. After stirring for 5 minutes and leaving it on the sedimentation promoting table using a magnet for 90 seconds, the microplate is moved to 90 on the pattern judging table.
The presence / absence of immune reaction was determined by inclining at 60 degrees for 2 seconds to flow out particles from the bottom of the well of the microplate to form an aggregation pattern. The combination of the aggregation patterns of the first to third wells was used to determine whether the measurement sample was positive or negative. Here, it was determined that the flow start length ≦ 3.00 mm was positive (+) and> 3.00 mm was negative (−). The final judgment was made from the results of the first to third wells, and the results are shown in Table 2. The length in Table 2 is the length of the flow start, and the unit is mm. For samples in which the first and second wells are + and the third well is-
The final determination was made by determining whether or not aggregation due to a non-specific reaction was included, based on the difference in the flow lengths of the first well and the second well. Here, the difference in the length of the flow start is 0.6 mm
When the above is the case, it is determined that the first well contains agglutination due to a non-specific reaction. (0.6 mm corresponds to a reproducibility width ± 1 tube in the agglutination method.) For all of the measured samples (1) to (8), the same measurement results as RIA were obtained as shown in Table 2.

【0023】[0023]

【表2】 ※ (1)、(2):HBs抗原を含有する希釈検体 (3)、(4):RIA陽性検体 (5)、(6):RIA陰性検体 (7)、(8):RIA陰性であるが、従来の間接凝集免疫測定方法では判 定不能となる検体[Table 2] * (1), (2): HBs antigen-containing diluted sample (3), (4): RIA positive sample (5), (6): RIA negative sample (7), (8): RIA negative However, specimens that cannot be determined by conventional indirect agglutination immunoassays

【0024】[0024]

【発明の効果】本発明の間接凝集免疫測定方法は、非特
異反応によらず一回の測定で検体の陽性・陰性の判定を
行うことができ、かつ高感度な測定方法である。従来の
定性試験において陽性・陰性を判定することができなか
った検体も、本発明によれば一回の測定で判定すること
ができ、それに伴い必要な検体のみ定量試験を行えば良
く、検査時間を短縮することができる。
INDUSTRIAL APPLICABILITY The indirect agglutination immunoassay method of the present invention is a highly sensitive assay method capable of determining positive / negative of a sample by a single measurement regardless of non-specific reaction. According to the present invention, it is possible to make a determination in a single measurement even for a sample that could not be determined as positive or negative in a conventional qualitative test, and accordingly, a quantitative test may be performed only for a necessary sample. Can be shortened.

フロントページの続き (56)参考文献 特開 平8−327628(JP,A) 特開 昭62−15464(JP,A) 特開 平8−327629(JP,A) 特開 昭60−256057(JP,A) 特開 平11−101803(JP,A) 特開 平9−89893(JP,A) 特開 昭55−111839(JP,A) (58)調査した分野(Int.Cl.7,DB名) G01N 33/53 - 33/579 Continuation of front page (56) Reference JP-A-8-327628 (JP, A) JP-A-62-15464 (JP, A) JP-A-8-327629 (JP, A) JP-A-60-256057 (JP , A) JP-A-11-101803 (JP, A) JP-A-9-89893 (JP, A) JP-A-55-111839 (JP, A) (58) Fields investigated (Int.Cl. 7 , DB) Name) G01N 33/53-33/579

Claims (4)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 1つの検体について、検体溶液を含む第
1ウェルと、反応抑制物質を含有する検体溶液を含む第
2ウェルと、第1ウェルよりも希釈倍率の高い検体溶液
を含む第3ウェルとを用意し、これらの3つのウェルに
おいて測定試薬との免疫反応を行い、得られた凝集結果
から非特異反応によらず検体の陽性・陰性を判定するこ
とができる間接凝集免疫測定方法。
1. For one sample, a first well containing a sample solution, a second well containing a sample solution containing a reaction-inhibiting substance, and a third well containing a sample solution having a higher dilution ratio than the first well. An indirect agglutination immunoassay method capable of determining the positive / negative of a sample based on the obtained agglutination result without depending on the nonspecific reaction, by preparing an immunoassay with a measurement reagent in these three wells.
【請求項2】 第2ウェルの検体濃度は第1ウェルと同
濃度であり、第3ウェルの検体濃度は非特異反応による
凝集が起こらない濃度であることを特徴とする請求項1
に記載の間接凝集免疫測定方法。
2. The concentration of the sample in the second well is the same as that of the first well, and the concentration of the sample in the third well is a concentration at which aggregation due to a non-specific reaction does not occur.
The indirect agglutination immunoassay method according to.
【請求項3】 第2ウェルの反応抑制物質の含有量と第
3ウェルの希釈倍率とを陽性検体について予め凝集が同
程度起こるように調整された請求項1乃至2に記載の間
接凝集免疫測定方法。
3. The indirect agglutination immunoassay according to claim 1, wherein the content of the reaction-inhibiting substance in the second well and the dilution ratio in the third well are adjusted in advance so that the agglutination occurs to the same extent in the positive sample. Method.
【請求項4】 第3ウェルの希釈倍率が原検体の32倍
以上である請求項1乃至3に記載の間接凝集免疫測定方
法。
4. The indirect agglutination immunoassay method according to claim 1, wherein the dilution ratio of the third well is 32 times or more that of the original sample.
JP34193397A 1997-11-28 1997-11-28 Indirect agglutination immunoassay Expired - Fee Related JP3368531B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP34193397A JP3368531B2 (en) 1997-11-28 1997-11-28 Indirect agglutination immunoassay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP34193397A JP3368531B2 (en) 1997-11-28 1997-11-28 Indirect agglutination immunoassay

Publications (2)

Publication Number Publication Date
JPH11160315A JPH11160315A (en) 1999-06-18
JP3368531B2 true JP3368531B2 (en) 2003-01-20

Family

ID=18349887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP34193397A Expired - Fee Related JP3368531B2 (en) 1997-11-28 1997-11-28 Indirect agglutination immunoassay

Country Status (1)

Country Link
JP (1) JP3368531B2 (en)

Also Published As

Publication number Publication date
JPH11160315A (en) 1999-06-18

Similar Documents

Publication Publication Date Title
AU670489B2 (en) Light scatter-based immunoassay without particle self aggregation
EP0030087A1 (en) Immunoassay method and apparatus and kit for carrying out the method
JPH09509248A (en) Test method
JPWO2003005031A1 (en) Carrier particle latex for measuring reagent and measuring reagent
JP7483168B2 (en) Ferritin measurement reagent
US5202269A (en) Method for immunochemical determination of hapten
WO2010013525A1 (en) Method of assaying complex and kit to be used therefor
JP3771413B2 (en) Antiphospholipid antibody measuring reagent, method for producing the same, and antiphospholipid antibody measuring method
JP3368531B2 (en) Indirect agglutination immunoassay
JP2682697B2 (en) Immunoassay reagents and immunoassays
JP3220546B2 (en) Method for measuring antigen or antibody in the presence of immune complex
JP4556605B2 (en) Target substance measurement method and reagent
JP2745705B2 (en) Antigen / antibody assay
JP2005512074A (en) Method for reducing non-specific assembly of latex microparticles in the presence of serum or plasma
JP2004117068A (en) Immunoassay reagent and immunoassay method
JPH08292192A (en) Immunoassary
JP2004012170A (en) Method for immunological measurement and measuring kit
JPH11248703A (en) Immunological method for measuring free hapten
JPH0921808A (en) Determination of protein by nephelometry and turbidity analysis not affected by excessive antigen
CN114563578A (en) Diagnostic kit for human membranous nephropathy
JP3692055B2 (en) Determination method of antigen-antibody reaction
JP2004212383A (en) Carrier particles for measurement reagent and the measurement reagent
JP2005049264A (en) Measuring method and measuring reagent of target material
JPH07174761A (en) Measuring method of analyte by agglutination
JP2002181822A (en) Immunoassay reagent and immunoassay method

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees